These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31658197)

  • 21. The Pre-Exposure Prophylaxis-Stigma Paradox: Learning from Canada's First Wave of PrEP Users.
    Grace D; Jollimore J; MacPherson P; Strang MJP; Tan DHS
    AIDS Patient Care STDS; 2018 Jan; 32(1):24-30. PubMed ID: 29185801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MPrEP+ study protocol: a prospective cohort study assessing the feasibility and acceptability of an HIV pre-exposure prophylaxis (PrEP) strategy for male clients of female sex workers in Kisumu, Kenya.
    Mantell J; Franks J; Zerbe A; Lamb MR; Reed DM; Omollo D; Lahuerta M; Naitore D; El-Sadr WM; Agot K
    BMJ Open; 2022 Nov; 12(11):e064037. PubMed ID: 36332953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Piloting a partially self-financed mode of human immunodeficiency virus pre-exposure prophylaxis delivery for men who have sex with men in Hong Kong.
    Lee SS; Kwan TH; Wong NS; Lee KCK; Chan DPC; Lam TTN; Lui GCY
    Hong Kong Med J; 2019 Oct; 25(5):382-391. PubMed ID: 31619578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
    Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
    HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
    Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
    Özdener AE; Park TE; Kalabalik J; Gupta R
    Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?
    Taramasso L; Riccardi N; Del Puente F; Bruzzone B; Ripamonti D; D'Ambrosio B; Viscoli C; Di Biagio A
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):168-170. PubMed ID: 29166777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
    Mugwanya KK; Baeten JM
    Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Research advances in HIV pre-exposure prophylaxis drug].
    Liu QZ; Yang X; Xu P; Qin QQ; Tang HL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Dec; 43(12):2036-2040. PubMed ID: 36572482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
    Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
    Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.
    Abdool Karim SS; Baxter C; Abdool Karim Q
    Antivir Ther; 2022 Apr; 27(2):13596535211067589. PubMed ID: 35499171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review.
    Mayer KH; Agwu A; Malebranche D
    Adv Ther; 2020 May; 37(5):1778-1811. PubMed ID: 32232664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
    Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN
    Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.
    Landovitz RJ; Beymer M; Kofron R; Amico KR; Psaros C; Bushman L; Anderson PL; Flynn R; Lee DP; Bolan RK; Jordan WC; Tseng CH; Dierst-Davies R; Rooney J; Wohl AR
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):501-511. PubMed ID: 28902074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
    Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
    Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ;
    JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure Prophylaxis.
    Madrasi K; Chaturvedula A; Haberer JE; Sale M; Fossler MJ; Bangsberg D; Baeten JM; Celum C; Hendrix CW
    J Clin Pharmacol; 2017 May; 57(5):606-615. PubMed ID: 27922719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-exposure prophylaxis (PrEP) for men who have sex with men in Europe: review of evidence for a much needed prevention tool.
    Reyniers T; Hoornenborg E; Vuylsteke B; Wouters K; Laga M
    Sex Transm Infect; 2017 Aug; 93(5):363-367. PubMed ID: 27872326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.